Aarkstore.com announces, a new market research report is available in its vast collection:
China Osteoporosis Market Analysis and Forecast, 2007 – 2015
Summary
The Chinese Osteoporosis drug market is expected to grow at a CAGR of 14.4% from 2007 to 2015.
Increased prevalence of Osteoporosis among Chinese female population is the principal growth driver of the Osteoporosis drug market. The other key growth drivers for Chinese Osteoporosis market include increasing elderly aged population, rising living standards of the Chinese people and increasing awareness and bone health education.
Geographical analysis of Chinese Osteoporosis drug market shows that there is a huge growth potential for Osteoporosis drug in many cities including Shanghai, Beijing, Guangzhou, and Hangzhou.
Bisphosphonate is the leading Osteoporosis drug class in China for Osteoporosis treatment and is expected to remain so for next few years.
To gain a competitive advantage, market players should develop cost-competitive drugs with easy dosage pattern, which promote bone building effectively.
Table of Contents :
1. Executive Summary
2. China Osteoporosis Market
2.1. Market Overview
2.2. Growth Drivers and Opportunities
2.3. Recent Market Developments
2.4. Competitive Strategies
2.5. Future Outlook
2.6. Driving Factor Analysis of China Osteoporosis Market
2.6.1. Demand Side Drivers
2.6.2. Supply Side Drivers
2.6.3. Restraints
2.6.4. Opportunities
2.6.5. Key Competitive Points
3. China Osteoporosis Market Share (2007 – 2015)
3.1. By Drug Class – Osteoporosis Market Share & Forecast
3.2. By Drug Market Share – Osteoporosis Market Share & Forecast
4. Osteoporosis Drugs Classes Market & Forecast (2007 – 2015)
4.1. China Bisphosphonate Market & Forecast
4.2. China Selective Estrogen Receptor Modulators (SERM) Market & Forecast
4.3. China Parathyroid Hormone (PTH) Market & Forecast
4.4. China Calcitonin Market & Forecast
5. Osteoporosis Drugs Market Analysis & Forecast (2007 – 2015)
5.1. Bisphosphonate Drugs Market Analysis
5.1.1. Fosamax (Alendronate)
5.1.2. Bonviva/Boniva (Ibandronic Acid)
5.1.3. Reclast/Aclasta
5.1.4. Actonel (Risedronate)
5.2. SERMs Drugs Market Analysis
5.2.1. Evista (Raloxifene)
5.2.2. Viviant/ Conbriza (Bazedoxifene)
5.3. Parathyroid Hormone Drugs Market Analysis
5.3.1. Forteo
5.4. Calcitonin Drugs Market Analysis
5.4.1. Miacalcin
5.5. Prolia (Denosumab)
6. Pipeline Drugs in Osteoporosis Market Analysis
6.1. Odanacatib (MK 0822)
6.2. Aprela (Bazedoxifene)
7. Recommendations
7.1. Market Strategy for Success
7.2. Barriers to be Considered
7.3. Future Assumption
For more related Reports Plz follow The link:
http://www.aarkstore.com/search/viewresults.asp?search=Osteoporosis&PubId=&pagenum=1
For More details Plz do contact :
Aarkstore.com
Contact: Marketing team
Mob.No.918149852585
Email: enquiry@aarkstore.com/
